A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice

Autor: Brandys, Pascal, Montagutelli, Xavier, Merenkova, Irena, Barut, Güliz T, Thiel, Volker, Schork, Nicholas J, Trüeb, Bettina, Conquet, Laurine, Deng, Aihua, Antanasijevic, Aleksandar, Lee, Hyun-Ku, Valière, Martine, Sindhu, Anoop, Singh, Gita, Herold, Jens

Publikováno v: Brandys, Pascal; Montagutelli, Xavier; Merenkova, Irena; Barut, Güliz T; Thiel, Volker; Schork, Nicholas J; Trüeb, Bettina; Conquet, Laurine; Deng, Aihua; Antanasijevic, Aleksandar; Lee, Hyun-Ku; Valière, Martine; Sindhu, Anoop; Singh, Gita; Herold, Jens (2022). A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Frontiers in immunology, 13(912898), p. 912898. Frontiers Research Foundation 10.3389/fimmu.2022.912898
Frontiers in Immunology
Frontiers in Immunology, 2022, 13, pp.912898. ⟨10.3389/fimmu.2022.912898⟩

PB and JH are the founders and owners of Phylex BioSciences, Inc., the company that holds IP related to RBD-NP; PB is a named inventor on several RBD-NP vaccine patents; AD is employed by BTS Research; GS and H-KL are employed by Abeomics, Inc.; AS w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cabd8f3108f57b9985f492f0e937e079
https://boris.unibe.ch/171536/1/fimmu-13-912898.pdf